Medical/Pharmaceuticals
ImmVira Announces Preclinical and Clinical Data to Be Presented at the 2021 ASCO and AACR Annual Meeting
SHENZHEN, China, April 8, 2021 /PRNewswire/ -- ImmVira today announces that the company will be presenting its first innovative product, MVR-T3011, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting onJune 4-8 2021. Results from the first Phase 1 study of MVR-T3011 as an intr...
2021-04-08 20:47
2111
Hyundai Bioscience leads in the repurposing of Niclosamide
SEOUL, South Korea, April 8, 2021 /PRNewswire/ -- A research paper by a South Korean bio tech company that demonstrated the drug repurposing of Niclosamide, an anthelmintic known to have excellent therapeutic efficacy against novel coronavirus infection (COVID-19), was published in the world-reno...
2021-04-08 17:17
1742
Bridge Biotherapeutics Announces Initiation of Phase 1/2 Clinical Trial of BBT-176 in EGFR-Mutant NSCLC with C797S
SEONGNAM, South Korea, April 6, 2021 /PRNewswire/ -- Bridge Biotherapeutics Inc.(288330 KQ), a clinical-stage biotech company headquartered in Seongnam, Republic of Korea, announced that the company has initiated the Phase 1/2 clinical trial assessing safety, tolerability, and anti-tumor activity...
2021-04-07 06:00
5224
Brattea, a Leading Renal Denervation Company in China, Completes over $US20 Million Series B+ Financing, led by Kuanping Capital
SHANGHAI, April 6, 2021 /PRNewswire/ -- Brattea, a leading renal denervation (RDN) medical technology company inChina, announced today its successful completion of over$US20 million Series B+ financing led by healthcare private equity fund Kuanping Capital. New investors include Hengxu Capital, P...
2021-04-06 20:00
40954
MitoImmune Received FDA Clearance of IND Application for MIT-001, a Novel Anti-Inflammatory/Anti-Necrotic Therapy for Oral Mucositis in CCRT patients with Head and Neck Cancer
- MitoImmune
2021-04-06 20:00
2718
US FDA Approved Jemincare to Initiate Clinical Trial of Neutralizing Antibody JMB2002
SHANGHAI, April 2, 2021 /PRNewswire/ -- On March 31, 2021, Jemincare group announced that their anti-SARS-CoV-2 neutralizing antibody, JMB2002, independently developed by Jemincare Shanghai Research Center, was approved by FDA for clinical trial inthe United States. Preclinical data showed that ...
2021-04-02 13:40
4202
Neurophth Announces IND Approval by the NMPA for Leber Hereditary Optic Neuropathy Gene Therapy
WUHAN and SUZHOU, China, April 1, 2021 /PRNewswire/ -- Neurophth Biotechnology Ltd., a fully-integrated genomic medicines company developing adeno-associated viral (AAV)-delivered gene therapies for the treatment of ocular diseases, recently announced the Center for Drug Evaluation (CDE) of China...
2021-04-01 20:39
4971
Molecular Data Inc. intends to further upgrade its digital tools using Blockchain
SHANGHAI, April 1, 2021 /PRNewswire/ -- Molecular Data Inc. ("Molecular Data" or the "Company") (Nasdaq: MKD), a leading technology-driven platform inChina's chemical industry, announced that it has signed a cooperation agreement with Dalian Lianhua Chemical Co., Ltd. ("Dalian Lianhua"), a leadin...
2021-04-01 19:00
2244
Jolly Good Newly Establishes CBT VR Specialist Department with Clinical Psychiatrists
TOKYO, April 1, 2021 /PRNewswire/ -- Leading Japanese medical VR company Jolly
Good Inc. has recently established a specialized DTx Division to develop
digital therapeutics (hereinafter "DTx") using VR and AI technologies.
Logo: https://kyodonewsprwire.jp/img/202103313079-O1-CAsOT26u
2021-04-01 16:00
1207
Yingli Pharma announce promising topline results of a Phase II registration study for treatment of relapsed/refractory follicular lymphoma with the once daily oral PI3Kδ inhibitor, linperlisib
* Linperlisib provides significant clinical improvement in the treatment for patients with relapsed and/or refractory follicular lymphoma * Linperlisib has a differentiated and well manageable safety profile SHANGHAI ,March 31, 2021 /PRNewswire/ -- Shanghai Yingli Pharmaceutical Co., Ltd. (Y...
2021-04-01 14:09
1303
Gracell Biotechnologies Signs Agreement with Lonza to Manufacture Gracell's FasTCAR Product Candidates in the U.S.
SUZHOU, China and PALO ALTO, Calif., March 31, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ:GRCL)("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment of cancer, today ...
2021-03-31 20:45
3160
Gracell Biotechnologies Announces Enrollment of First Patient in Registrational Phase 1/2 Clinical Study for GC007g, an Allogeneic CAR-T Cell Therapy for the Treatment of Relapsed or Refractory B-ALL
SUZHOU and SHANGHAI, China, March 31, 2021 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, announced that they have enr...
2021-03-31 20:00
9774
AffaMed Therapeutics and SIFI Announce Joint Venture to Serve Greater China Market
SHANGHAI, March 31, 2021 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to addressing critical unmet patient need in ophthalmic, neurological and psychiatric disorders, and SIFI S.p.A. ("SIFI"), a leading international ophthalmic com...
2021-03-31 19:30
1970
3SBio announces 2020 annual results, tapping integrated platform advantages for steady growth
SHANGHAI, March 30, 2021 /PRNewswire/ -- Chinese leading biopharmaceutical company 3SBio (01530.HK) today unveiled its 2020 full-year results. The Company maintained stable profitability despite the huge challenge amid the COVID-19 pandemic, while ushering in new milestones. It once again demonst...
2021-03-31 09:11
2863
ImmuneOncia and 3D Medicines Signed Exclusive License Agreement to Develop, Manufacture and Commercialize IMC-002 in Greater China
* 3D Medicines to Lead the Manufacture, Clinical Development and Commercialization of IMC-002 for Oncology indications inGreater China * ImmuneOncia to Receive potentially up to $470.5M including $8M Upfront, and Future Development and Commercial Milestone Payments, plus Tiered Royalties on N...
2021-03-31 09:00
1986
AffaMed Therapeutics Announces Completion of over US$170 Million Series B Financing Led by Lake Bleu Capital to Further Development of Ophthalmic and Neuroscience Pipeline
SHANGHAI, March 30, 2021 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a global clinical-stage biopharmaceutical company dedicated to addressing critical unmet patient need in ophthalmic, neurological and psychiatric disorders, today announced the completion of over US$170 million in Series B...
2021-03-30 19:30
1640
Instylla Announces Enrollment of Initial Patients in the Embrace™ Hydrogel Embolic System Global Randomized Multi-Center Clinical Trial
Pivotal study to evaluate the use of novel liquid embolic versus standard of care in treating malignant and benign hypervascular tumors BEDFORD, Mass., March 30, 2021 /PRNewswire/ -- Instylla, Inc., a privately held company developing next-generation liquid embolics for peripheral vascular embol...
2021-03-30 19:02
951
China Biologic Reports Financial Results for the Fourth Quarter and Fiscal Year 2020
BEIJING, March 29, 2021 /PRNewswire/ -- China Biologic Products Holdings, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company inChina, today announced its financial results for the fourth quarter and fiscal year of 2020. Fourt...
2021-03-30 04:30
4344
Fosun Pharma Announces 2020 Annual Results
Multiple Innovative Products Launched with Significant Improvement in the Capability of Global Commercialization Net Profit Attributable to Shareholders After Extraordinary G/L Increases 21.65% YOY toRMB2,718 Million SHANGHAI, March 29, 2021 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (...
2021-03-30 00:38
4548
HOYA Confirm the Long Term Technical Collaboration and Supply Agreement Related to Endoscopic Ultrasound Systems
TOKYO, March 29, 2021 /PRNewswire/ -- HOYA Corporation (TSE:7741, "HOYA") today confirms that the five year contract announced onJuly 6, 2020 for technical collaboration and supply of diagnostics ultrasound systems and ultrasound sensor with Hitachi, will become effective as ofMarch 31st of 2021....
2021-03-29 22:00
2765
Week's Top Stories
Most Reposted
Another 'Reason to Travel': Agoda and Singapore Tourism Board Renew Partnership to Boost Travel to Singapore
[Picked up by 350 media titles]
2024-06-19 11:00
MIFB 2024 ENLISTS F&B EXPERTS TO SPEAK ON THE LATEST IN INDUSTRY TRENDS AND THE FUTURE OF FOOD
[Picked up by 335 media titles]
2024-06-20 16:24
k-ID Closes $45 Million Series A from Andreessen Horowitz and Lightspeed Venture Partners to Set a New Global Benchmark for Age-appropriate Gaming Experiences
[Picked up by 318 media titles]
2024-06-25 21:00
New Study Finds Cybersecurity as Top Concern Among Automotive Manufacturers
[Picked up by 317 media titles]
2024-06-19 08:05THEIR ROYAL HIGHNESSES THE DUKE AND DUCHESS OF EDINBURGH CELEBRATE THE GRAND OPENING OF THE PENINSULA LONDON, BELGRAVIA
[Picked up by 313 media titles]
2024-06-19 11:38
Most Read
Another 'Reason to Travel': Agoda and Singapore Tourism Board Renew Partnership to Boost Travel to Singapore
2024-06-19 11:00
15653
MIFB 2024 ENLISTS F&B EXPERTS TO SPEAK ON THE LATEST IN INDUSTRY TRENDS AND THE FUTURE OF FOOD
2024-06-20 16:24
13314
New Study Finds Cybersecurity as Top Concern Among Automotive Manufacturers
2024-06-19 08:05
9440
